Act1 is a Negative Regulator in T and B Cells Via Direct Inhibition of STAT3.
Cun-Jin Zhang,Chenhui Wang,Meiling Jiang,Chunfang Gu,Jianxin Xiao,Xing Chen,Bradley N. Martin,Fangqiang Tang,Erin Yamamoto,Yibo Xian,Han Wang,Fengling Li,R. Balfour Sartor,Howard Smith,M. Elaine Husni,Fu-Dong Shi,Ji Gao,Julie Carman,Ashok Dongre,Susan C. McKarns,Ken Coppieters,Trine N. Jørgensen,Warren J. Leonard,Xiaoxia Li
DOI: https://doi.org/10.1038/s41467-018-04974-3
IF: 16.6
2018-01-01
Nature Communications
Abstract:Although Act1 (adaptor for IL-17 receptors) is necessary for IL-17-mediated inflammatory responses, Act1 - (but not Il17ra- , Il17rc- , or Il17rb -) deficient mice develop spontaneous SLE- and Sjögren’s-like diseases. Here, we show that Act1 functions as a negative regulator in T and B cells via direct inhibition of STAT3. Mass spectrometry analysis detected an Act1–STAT3 complex, deficiency of Act1 (but not Il17ra -, Il17rc- , or Il17rb ) results in hyper IL-23- and IL-21-induced STAT3 activation in T and B cells, respectively. IL-23R deletion or blockade of IL-21 ameliorates SLE- and Sjögren’s-like diseases in Act1 −/− mice. Act1 deficiency results in hyperactivated follicular Th17 cells with elevated IL-21 expression, which promotes T–B cell interaction for B cell expansion and antibody production. Moreover, anti-IL-21 ameliorates the SLE- and Sjögren’s-like diseases in Act1-deficient mice. Thus, IL-21 blocking antibody might be an effective therapy for treating SLE- and Sjögren’s-like syndrome in patients containing Act1 mutation.